Zydus Lifesciences and CSIR-CDRI to Develop Drug for CKD-Induced Osteoporosis

Zydus Lifesciences Ltd and CSIR-Central Drug Research Institute Lucknow have signed a collaborative research agreement to develop a best-in-class drug for chronic kidney disease (CKD) induced osteoporosis. The agreement was signed on 17th September 2024 at Zydus Research Centre, Ahmedabad. The research will focus on the discovery of small molecule inhibitors of Sclerostin, a protein that plays a key role in the dysregulation of bone metabolism. Any drug candidate emerging from the efforts will be developed by Zydus for India and other markets. The collaboration aims to provide effective and affordable therapies for CKD patients, improving their quality of life.